{"filing":{"accession_number":"0001193125-26-324202","cik":"0001422143","ticker":"KURA","company_name":"Kura Oncology, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-24","primary_document":"d53075d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/d53075d8k.htm"},"events":[{"id":21778,"run_id":19648,"accession_number":"0001193125-26-324202","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on amendments to executive employment agreements for three named officers (Troy E. Wilson, Ph.D., J.D., Brian Powl, and Kathleen Ford) that modify severance provisions, including cash payments, equity acceleration, and COBRA continuation benefits triggered by termination or resignation events, particularly in connection with a Corporate Transaction. This is a classic compensatory arrangement disclosure under Item 5.02(e).","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21501,"accession_number":"0001193125-26-324202","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on amendments to executive employment agreements for three named officers (Troy E. Wilson, Ph.D., J.D., Brian Powl, and Kathleen Ford) that modify severance provisions, including cash payments, equity acceleration, and COBRA continuation benefits triggered by termination or resignation events, particularly in connection with a Corporate Transaction. This is a classic compensatory arrangement disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:18:36.385166+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21501,"accession_number":"0001193125-26-324202","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on amendments to executive employment agreements for three named officers (Troy E. Wilson, Ph.D., J.D., Brian Powl, and Kathleen Ford) that modify severance provisions, including cash payments, equity acceleration, and COBRA continuation benefits triggered by termination or resignation events, particularly in connection with a Corporate Transaction. This is a classic compensatory arrangement disclosure under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:18:36.385166+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-07-29"}]}